RESUMO
AIM: The aim of this study was to gather information about patients' needs prior to transferring from an acute care facility to a rehabilitation setting that could assist patients to engage actively in rehabilitation activities upon entering the unit. BACKGROUND: The provision of information is an important aspect of health care as it assists patients to become informed and actively participate in this care. Improved recovery has been associated with patients' adherence to care regimes. METHOD: Semi-structured interviews were undertaken with a convenient sample of nine patients shortly after admission/transfer to a rehabilitation unit and with four of these patients after discharge. The intent was to learn what information patients receive prior to admission to the rehabilitation unit, whether this information is useful and whether different information would be more useful to facilitate patients' engagement in the activities central to rehabilitation treatment. RESULTS: Interviews revealed that, generally, patients received very little information about what to expect on admission to the rehabilitation unit and patients' engagement was more dependent on perceptions about rehabilitation. Thematic analysis identified that, in general, rehabilitation was perceived as 'a ticket out' and 'a good thing'. In relation to provision of information of participants identified that 'doesn't matter that I don't know'; 'information is not always meaningful' and 'I will adjust in my own time'. RELEVANCE TO CLINICAL PRACTICE: Health professionals need to recognize that patients are often compliant with decisions made while they are inpatients of the current health care system. Even though patients may 'actively participate' in rehabilitation processes it is often still as a passive recipient of health care.
Assuntos
Idoso/psicologia , Avaliação Geriátrica/métodos , Avaliação das Necessidades/organização & administração , Admissão do Paciente , Educação de Pacientes como Assunto/normas , Participação do Paciente/métodos , Atividades Cotidianas , Adaptação Psicológica , Idoso de 80 Anos ou mais , Feminino , Geriatria , Unidades Hospitalares , Humanos , Masculino , Pessoa de Meia-Idade , Pesquisa Metodológica em Enfermagem , Alta do Paciente/normas , Participação do Paciente/psicologia , Transferência de Pacientes/normas , Queensland , Centros de Reabilitação , Inquéritos e QuestionáriosRESUMO
Primary infection with drug-resistant HIV-1 is well documented. We have followed up patients infected with such viruses to determine the stability of resistance-associated mutations. Fourteen patients who experienced primary infection with genotypic evidence of resistance were followed for up to 3 years. Drug resistance-associated mutations persisted over time in most patients studied. In particular, M41L, T69N, K103N, and T215 variants within reverse transcriptase (RT) and multidrug resistance demonstrated little reversion to wild-type virus. By contrast, Y181C and K219Q in RT, occurring alone, disappeared within 25 and 9 months, respectively. Multidrug resistance in 2 patients was found to be stable for up to 18 months, the maximum period studied. We conclude that certain resistance-associated mutations are highly stable and these data support the recommendation that all new HIV diagnoses in areas where primary resistance may occur should undergo genotyping irrespective of whether the date of seroconversion is known.
Assuntos
Fármacos Anti-HIV/farmacologia , Farmacorresistência Viral/genética , Inibidores da Protease de HIV/farmacologia , HIV-1/efeitos dos fármacos , Inibidores da Transcriptase Reversa/farmacologia , Genótipo , Infecções por HIV/tratamento farmacológico , Infecções por HIV/virologia , Protease de HIV/genética , Transcriptase Reversa do HIV/genética , Soropositividade para HIV , Humanos , Mutação , Fatores de TempoRESUMO
The objective of the study was to determine the cost implications of patterns of treatment for patients with external genital warts. A retrospective case note review was carried out at six genitourinary medicine (GUM) clinics in the UK. Significant variations in the total costs of care were observed across the clinics and across the choice of therapy. The cost per successful outcome was pound 221.81 for males and pound 211.07 for females. A minority of patients accounted for the majority of costs, for example the 30.1% of male patients who recorded six or more visits contributed 66.2% of the total cost. Costs also varied significantly by therapy sequence chosen. Patients who remained on their initial therapy experienced the lowest costs, with the extent to which patients shifted therapies substantially impacting on costs. Therapy sequences involving podophyllin were found to be the most expensive options in achieving a completed episode of care. We concluded that a high proportion of costs for GUM clinics is due to the failure of the initial therapy and by subsequent therapy switching. A greater emphasis on the selection of alternative treatment options, such as the patient-applied therapies, may help to reduce overall costs of care.
Assuntos
Condiloma Acuminado/economia , Condiloma Acuminado/terapia , Instituições de Assistência Ambulatorial , Inglaterra , Feminino , Doenças dos Genitais Femininos/economia , Doenças dos Genitais Femininos/terapia , Doenças dos Genitais Masculinos/economia , Doenças dos Genitais Masculinos/terapia , Custos de Cuidados de Saúde/estatística & dados numéricos , Humanos , Masculino , Prontuários Médicos , Visita a Consultório Médico/economia , Visita a Consultório Médico/estatística & dados numéricos , Estudos Retrospectivos , País de GalesRESUMO
Our objective was to identify patterns of treatment and resources used in achieving complete clearance of external genital warts (EGWs) A retrospective case note review was carried out at six genitourinary medicine (GUM) clinics in the UK. Case notes from 2366 patients presenting with EGWs were reviewed and 1200 patients with complete episodes of care were identified. Analysis showed that staff-applied therapy dominated treatment practice but there was considerable diversity in treatment modalities across study sites. The average number of visits was 5.71 visits for males: 6.25 visits for females but a substantial minority of patients attended significantly in excess of these averages. Approximately two-thirds of patients failed to achieve complete clearance of warts with their initial therapy. There is little consistency in treatment patterns of care for EGWs across the sites studied. Initial therapy choices are largely ineffective, requiring changes in treatment modality and multiple clinic visits. Increased utilization of patient-applied therapies might result in increased cost effectiveness.
Assuntos
Condiloma Acuminado/terapia , Visita a Consultório Médico/estatística & dados numéricos , Padrões de Prática Médica , Adulto , Distribuição por Idade , Instituições de Assistência Ambulatorial , Cáusticos/administração & dosagem , Terapia Combinada , Crioterapia , Feminino , Humanos , Ceratolíticos/administração & dosagem , Masculino , Podofilina/administração & dosagem , Estudos Retrospectivos , Distribuição por Sexo , Resultado do Tratamento , Recusa do Paciente ao Tratamento/estatística & dados numéricos , Ácido Tricloroacético/administração & dosagem , Reino UnidoRESUMO
OBJECTIVES: To evaluate the steady-state blood plasma (BP), CSF and seminal plasma (SP) pharmacokinetics (PK) of twice-daily indinavir 400 mg and lopinavir/ritonavir. METHODS: Ten HIV-1-positive men on lopinavir/ritonavir participated in a PK study. PK sampling was performed before and 2 weeks after adding indinavir to lopinavir/ritonavir-containing regimens. BP, CSF and SP RNA levels, CD4 counts and blood chemistry were checked at baseline and 2 weeks after indinavir. RESULTS: At baseline: lopinavir parameters (n=10) in BP were within expected levels. Median lopinavir trough concentrations (n=5) in CSF and SP were below the limit of detection (BLD) (i.e. <10 ng/mL) and 248 ng/mL (range 96-2777), respectively. After indinavir: lopinavir C(max), C(min) and AUC(0-12) increased by 9%, 46% and 20%, respectively (P<0.32, P<0.32 and P<0.20). In two of four men lopinavir concentrations in CSF were detectable at 27 and 29 ng/mL. Median SP lopinavir concentration was 655 ng/mL (20-2734). Median indinavir PK parameters were C(max) 3365 ng/mL (range 2130-5194), C(min) 293 ng/mL (14-766), T(max) 2.25 h (1-3), AUC(0-12) 22452 ng/mL.h (11243-33661), and t(1/2) 2.8 h (1.4-3.7). Median indinavir concentrations in CSF and SP were 39 ng/mL (21-86) and 592 ng/mL (96-983). Two of eight men who initially had detectable BP viral load (VL) became BLD (<50 copies/mL) after the addition of indinavir, and in 2/4 men with low-level viraemia in SP (BPVL BLD) their SPVL became BLD after addition of indinavir. CONCLUSIONS: Adding indinavir 400 mg twice daily to lopinavir/ritonavir-containing regimens did not significantly alter the median lopinavir PK parameters. However, wide interpatient variability in lopinavir concentrations was seen. In contrast plasma indinavir levels were >80 ng/mL in seven of eight plasma samples, and all CSF and semen samples collected.
Assuntos
Infecções por HIV/metabolismo , Inibidores da Protease de HIV/farmacocinética , Indinavir/farmacocinética , Pirimidinonas/farmacocinética , Sêmen/metabolismo , Adulto , Área Sob a Curva , Contagem de Linfócito CD4 , Cromatografia Líquida de Alta Pressão , Combinação de Medicamentos , Inibidores da Protease de HIV/sangue , Inibidores da Protease de HIV/líquido cefalorraquidiano , HIV-1/metabolismo , Humanos , Indinavir/sangue , Indinavir/líquido cefalorraquidiano , Lopinavir , Masculino , Espectrometria de Massas , Pessoa de Meia-Idade , Pirimidinonas/sangue , Pirimidinonas/líquido cefalorraquidiano , RNA Viral/biossíntese , Carga ViralRESUMO
Sexually transmitted infections may enhance the sexual transmission of HIV-1. It is possible that loss of virological control in patients with such infections receiving antiretroviral therapy (ART) may even facilitate the transmission of drug-resistant HIV. We have recently demonstrated that in those on maximally suppressive ART this effect is reduced. We have examined the virus obtained from the blood plasma and seminal plasma of six HIV-1-infected men receiving poorly suppressive ART with acute urethritis for the presence of drug resistance-associated mutations. In four men with gonorrhoea the blood and seminal plasma HIV-1 had mutations conferring reduced susceptibility to one or more available drugs. In one of these men the viral load of drug-resistant virus in seminal plasma was 20-fold higher during gonorrhoea than following antibiotic treatment, with no change in blood plasma viral load. We conclude that in the presence of suboptimal ART, sexually transmitted infections may enhance the spread of drug-resistant HIV-1.
Assuntos
Farmacorresistência Viral , Gonorreia/complicações , Infecções por HIV/tratamento farmacológico , Infecções por HIV/transmissão , HIV-1/efeitos dos fármacos , Sêmen/virologia , Infecções Sexualmente Transmissíveis/complicações , Doença Aguda , Fármacos Anti-HIV/farmacologia , Fármacos Anti-HIV/uso terapêutico , Farmacorresistência Viral/genética , Quimioterapia Combinada , Infecções por HIV/virologia , Protease de HIV/genética , Transcriptase Reversa do HIV/genética , Humanos , Masculino , Mutação , Inibidores da Transcriptase Reversa/farmacologia , Inibidores da Transcriptase Reversa/uso terapêutico , Uretrite/complicações , Carga ViralRESUMO
The aim of the study was to compare the responses of homosexual men (HM) receiving a standard course of recombinant hepatitis B vaccine with those of healthcare workers vaccinated in the same hospital over the same period. Boosters for inadequate responders and repeat courses for non-responders were given. Forty of 61 (75.4%) of HM completing full follow-up were successfully vaccinated, compared with 128 of 129 (99.2%) female and 94 of 96 (97.9%) male health care workers (P<0.001). The response to hepatitis-B vaccination in healthy homosexual men is poor and significantly lower than healthcare workers vaccinated and followed up according to the same protocol.
Assuntos
Vacinas contra Hepatite B/imunologia , Homossexualidade , Vacinação , Adulto , Envelhecimento/imunologia , Estudos de Casos e Controles , Feminino , Seguimentos , Pessoal de Saúde , Anticorpos Anti-Hepatite/análise , Anticorpos Anti-Hepatite/biossíntese , Humanos , Esquemas de Imunização , Imunização Secundária , Masculino , Estudos Retrospectivos , Caracteres Sexuais , Vacinas de DNA/imunologia , Vacinas Sintéticas/imunologiaRESUMO
BACKGROUND: High seminal plasma HIV-1 RNA loads (SVL) have been reported during gonococcal, non-gonococcal and chlamydial urethritis in patients not taking antiretroviral therapy. OBJECTIVE: To examine if urethritis leads to increased SVL in HIV-positive patients taking antiretroviral therapy. METHODS: Men who had been taking therapy for at least 3 months were recruited: 24 had urethitis (PWU) and 16 were without urethritis (controls). At three visits, 1 week apart, blood plasma viral load (BVL) and SVL were assayed by quantitative polymerase chain reaction or the NASBA assay. RESULTS: Most subjects had undetectable SVL (18 PWU, 13 controls). Among those with undetectable BVL prior to first study visit, virus was undetectable in semen in 5/5 episodes of chlamydial urethritis, 6/7 episodes of non-gonococcal urethritis and 4/5 cases of gonococcal urethritis. Two PWU with undetectable BVL just prior to the first study visit had low to moderate SVL, which became undetectable by visit 2 following treatment. Of nine subjects with detectable SVL, eight had detectable BVL (3/3 controls and 5/6 PWU). Of these, 1/3 controls and 4/5 PWU (all with gonococcal urethritis) had poorly controlled BVL just prior to the first study visit. These four PWU had high SVL and one had higher levels in semen than in blood. This patient's SVL was reduced more than 20-fold following treatment for gonococcal urethritis. CONCLUSIONS: Effective antiretroviral therapy appeared to limit the effect of urethritis on SVL. When BVL was poorly controlled by antiretroviral therapy, high SVL occurred during gonococcal urethritis, increasing the potential risk of transmitting both wild type and drug resistant strains of HIV-1.